Bill Few Associates Inc. Sells 44 Shares of Stryker Co. (NYSE:SYK)

Bill Few Associates Inc. reduced its holdings in shares of Stryker Co. (NYSE:SYK) by 1.8% in the fourth quarter, HoldingsChannel reports. The fund owned 2,362 shares of the medical technology company’s stock after selling 44 shares during the period. Bill Few Associates Inc.’s holdings in Stryker were worth $850,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. D.B. Root & Company LLC boosted its holdings in Stryker by 3.8% in the fourth quarter. D.B. Root & Company LLC now owns 3,676 shares of the medical technology company’s stock worth $1,324,000 after acquiring an additional 135 shares in the last quarter. Mutual Advisors LLC boosted its stake in Stryker by 13.8% in the 4th quarter. Mutual Advisors LLC now owns 6,331 shares of the medical technology company’s stock worth $2,417,000 after purchasing an additional 769 shares in the last quarter. True North Advisors LLC purchased a new stake in Stryker during the 4th quarter valued at about $3,595,000. Traynor Capital Management Inc. bought a new stake in Stryker during the 4th quarter valued at about $324,000. Finally, Independent Wealth Network Inc. raised its holdings in Stryker by 6.1% in the fourth quarter. Independent Wealth Network Inc. now owns 677 shares of the medical technology company’s stock worth $244,000 after buying an additional 39 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on SYK. Truist Financial raised their price target on shares of Stryker from $380.00 to $409.00 and gave the company a “hold” rating in a research report on Wednesday, December 18th. Piper Sandler restated an “overweight” rating and issued a $420.00 price target (up previously from $380.00) on shares of Stryker in a research note on Wednesday, October 30th. BTIG Research lifted their price objective on Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Needham & Company LLC restated a “buy” rating and set a $442.00 target price on shares of Stryker in a research note on Tuesday, January 7th. Finally, Evercore ISI boosted their price objective on shares of Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Five research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $405.80.

Insider Buying and Selling at Stryker

In related news, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the sale, the chief executive officer now directly owns 100,027 shares in the company, valued at approximately $36,879,954.90. The trade was a 36.43 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.90% of the stock is currently owned by insiders.

Stryker Stock Down 1.4 %

Shares of SYK stock opened at $390.31 on Thursday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. Stryker Co. has a one year low of $307.23 and a one year high of $398.20. The company’s fifty day moving average price is $375.82 and its 200-day moving average price is $360.16. The company has a market capitalization of $148.79 billion, a price-to-earnings ratio of 41.83, a PEG ratio of 2.72 and a beta of 0.95.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, beating the consensus estimate of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The business had revenue of $5.49 billion for the quarter, compared to the consensus estimate of $5.37 billion. During the same period in the previous year, the business earned $2.46 earnings per share. The business’s revenue was up 11.9% on a year-over-year basis. Sell-side analysts expect that Stryker Co. will post 12.06 EPS for the current fiscal year.

Stryker Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be given a dividend of $0.84 per share. This is a positive change from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date is Tuesday, December 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. Stryker’s dividend payout ratio is currently 36.01%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.